HER-2 peptides p776 and F7, N-terminal-linked with Ii-Key tetramer (LRMK) help the proliferation of E75-TCR+ cells: The dependency of help on the side chains of LRMK-extended peptide pointed towards the T cell receptor

Oncology Reports

Volumn 19, Issue 6, 2008, Pages 1445-1452

  Li, Yufeng ^a   Ishiyama, Satoshi ^a   Matsueda, Satoko ^a   Tsuda, Naotake ^a   Ioannides, Constantin G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; HER2 neu; Ii Key peptide; MHC class II; T helper cells

Indexed keywords

ACETYLLEUCYLARGINYLMETHIONYLLYSINE EPSILON AMINOVALERIC ACID GLYCYLVALYLGLYCYLSERYLPROLYLTYROSYLVALYLSERYLARGINYLLEUCYLLEUCYLGLYCYLISOLEUCYLCYSTEINYLLEUCYLAMIDE; ACETYLLEUCYLARGINYLMETHIONYLLYSYLGLYCYLVALYLGLYCYLSERYLPROLYLTYROSYLVALYLSERYLARGINYLLEUCYLLEUCYLGLYCYLISOLEUCYLCYSTEINYLLEUCYLAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HLA DR ANTIGEN; HYBRID PROTEIN; NUCLEOTIDE DERIVATIVE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; LYMPHOCYTE ANTIGEN RECEPTOR; ONCOPROTEIN; PEPTIDE FRAGMENT;

AMINO TERMINAL SEQUENCE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; FEMALE; FUSION GENE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREGULATION; INTRADUCTAL CARCINOMA; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; AMINO ACID SEQUENCE; BREAST TUMOR; CELL CULTURE; CHEMICAL STRUCTURE; DRUG EFFECT; IMMUNOLOGY; INVARIANT CHAIN; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR GENETICS; PAGET NIPPLE DISEASE; PATHOLOGY; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, FUSION; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR CELLS, CULTURED;

EID: 48849103279     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Adams S and Humphreys RE: Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 25: 1693-1702, 1995.
2. Adams S, Albericio F, Alsina J, Smith ER and Humphreys RE: Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arzneimittelforschung 47: 1069-1077, 1997.
3. Xu M, Jackson R, Adams S and Humphreys RE: Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittelforschung 49: 791-799, 1999.
4. Humphreys RE, Adams S, Koldzic G, Nedelescu B, von Hofe E and Xu M: Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 18: 2693-2697, 2000.
5. Kallinteris NL, Lu X, Wu S, Hu H, Li Y, Gulfo JV, Humphreys RE and Xu M: Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine 21: 4128-4132, 2003.
6. Tuttle TM, Anderson BW, Thompson WE, et al: Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 4: 2015-2024, 1998.
7. Disis ML, Bernhard H, Shiota FM, et al: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88: 202-210, 1996.
8. Fisk B, Hudson JM, Kavanagh J, Wharton JT, Murray JL, Ioannides CG and Kudetka AP: Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides. Anticancer Res 17: 45-53, 1997.
9. Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD and Cheever MA: Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/ neu, oncogenic self-protein. J Immunol 156: 3151-3158, 1996.
10. Disis ML, Grabstein KH, Sleath PR, et al: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 5: 1289-1297, 1999.
11. Kuerer HM, Peoples GE, Sabin AA, et al: Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res 22: 583-592, 2002.
12. Knutson KL and Disis ML: IL-12 enhances the generation of tumour antigen- specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol 135: 322-329, 2004.
13. Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE and Murray JL: Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 53: 490-496, 2004.
14. Coulie PG, Brichard V, Van Pet A, et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180: 35-42, 1994.
15. Fisk B, Blevins TL, Wharton JT, et al: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117, 1995.
16. Peoples GE, Gurney JM, Hueman MT, et al: Clinical trials results of a Her-2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23: 7536-7545, 2005.
17. Lee TV, Johnston DA, Thomakos N, et al: Helper peptide G89 (HER-2:777-789) and G89-activated cells regulate the survival of effectors induced by the CTL epitope E75 (HER-2, 369-377). Correlation with the IFN-λ:IL-10 balance. Anticancer Res 22: 1481-1490, 2002.
18. + tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. Int J Oncol 24: 1413-1418, 2004.
19. Castilleja A, Carter D, Efferson CL, et al: Induction of tumor-reactive CTL by C-side chain variants of CTL epitope HER2/neu proto-oncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. J Immunol 169: 3545-3554, 2002.
20. + cells to methylene groups appended to tumor antigen determines their differentiation and death. Cancer Res 65: 2930-2937, 2005.
21. Bian H and Hammer J: Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34: 468-475, 2004.
22. Bian H, Reidhaar-Olson JF and Hammer J: The use of bioinformatics for identifying class II-restricted T-cell epitopes. Methods 29: 299-309, 2003.
23. Zavala-Ruiz Z, Sundberg EJ, Stone JD, et al: Exploration of the P6/ P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1. J Biol Chem 278: 44904-44912, 2003.
24. Zavala-Ruiz Z, Strug I, Walker BD, Norris PJ and Stern LJ: A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition. Proc Natl Acad Sci USA 101: 13279-13284, 2004.
25. Hennecke J and Wiley DC: Structure of a complex of the human T cell receptor (TCR) HA17, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J Exp Med 195: 571-581, 2002.
26. Salazar LG, Fikes J, Southwood S, et al: Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 9: 5559-5565, 2003.
27. + T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 121: 2031-2041, 2007.
28. Dellabona P, Peccoud J, Kappler J, Marrack P, Benoist C and Mathis D: Superantigens interact with MHC class II molecules outside of the antigen groove. Cell 62: 1115-1121, 1990.
29. Plaza R, Rodriguez-Sanchez JL and Juarez C: Staphylococcal enterotoxin B in vivo modulates both gamma interferon receptor expression and ligand-induced activation of signal transducer and activator of transcription 1 in T cells. Infect Immun 75: 306-313, 2007.
30. Wang L, Zhao Y, Li Z, et al: Crystal structure of a complete ternary complex of TCR, superantigen and peptide-MHC. Nat Struct Mol Biol 14: 169-171, 2007.
31. +T cells in the development of T helper type 1 responses. J Exp Med 195: 473-483, 2002.
32. + tumors. Cancer Immunol Immunother 56: 601-613, 2007.
33. + T lymphocytes. Nature 421: 852-856, 2003.